Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCR1 Biologics Sequence Review Report 2026: Natural cytotoxicity triggering receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of NCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MTNR1B Biologics Sequence Review Report 2026: Melatonin receptor type 1B Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MTNR1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MTNR1A Biologics Sequence Review Report 2026: Melatonin receptor type 1A Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MTNR1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MPL Biologics Sequence Review Report 2026: Thrombopoietin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MPL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MPIG6B Biologics Sequence Review Report 2026: Megakaryocyte and platelet inhibitory receptor G6b Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MPIG6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MSR1 Biologics Sequence Review Report 2026: Macrophage scavenger receptor types I and II Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MSR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MC5R Biologics Sequence Review Report 2026: Melanocortin receptor 5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MC5R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LTK Biologics Sequence Review Report 2026: Leukocyte tyrosine kinase receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LTK protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MC3R Biologics Sequence Review Report 2026: Melanocortin receptor 3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MC3R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LHCGR Biologics Sequence Review Report 2026: Lutropin-choriogonadotropic hormone receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LHCGR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LPAR6 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 6 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LPAR6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HTR7 Biologics Sequence Review Report 2026: 5-hydroxytryptamine receptor 7 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of HTR7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
243
244
245
246
247
>>
1905
>